■尽管有大量关于宫颈癌治疗策略的文献,专门针对晚期免疫疗法的文献计量分析,经常性,或转移性(A/R/M)宫颈恶性肿瘤仍未发现。本研究旨在通过提供包括一般特征在内的全面概述来解决这一差距,研究重点,进化的轨迹,以及这个研究不足的领域目前的新兴趋势。
■使用WebofScienceCoreCollection(WOSCC)进行了系统搜索,以识别2000年至2022年之间发表的与A/R/M宫颈癌相关的文章。Citespace和VOS查看器是用于确定研究重点的主要工具,有趣的未来模式,并评估作者之间的贡献和共同事件,机构,国家,和期刊。
■共识别出1,001篇原创文章,涉及来自66个国家和1,474个机构的6,387位作者,并在366种学术期刊上发表。美国贡献最大。最有成效的研究人员是莱顿大学医学中心的VanderBurgSH。《国际癌症和癌症研究杂志》被确定为最具生产力和影响力的期刊,分别。共引聚类分析突出显示了25个聚类,主要关注潜在的预测性生物标志物,基于树突状细胞的肿瘤疫苗,治疗性HPV疫苗接种,基于肽的癌症疫苗,肿瘤免疫微环境,过继细胞转移(ACT)。A/R/M宫颈癌免疫治疗研究的最新重要趋势包括ACT,CAR-T,和免疫检查点抑制剂(ICIs),如关键字和参考突发检测所示。
■这项开创性研究提供了A/R/M宫颈癌免疫治疗研究的详细前景。它强调了全球合作的重要性,丰富了我们对A/R/M宫颈癌免疫学的认识,扩大免疫疗法的潜在受益者,并探索各种疗法的临床应用,包括治疗性疫苗,过继细胞转移,ICIs,特别是与既定的治疗如化疗相结合,放射治疗,和靶向治疗。
UNASSIGNED: Despite extensive literature on therapeutic strategies for cervical cancer, a bibliometric analysis specifically focused on immunotherapy for advanced, recurrent, or metastatic (A/R/M) cervical malignancies remains unexplored. This study aims to address this gap by presenting a comprehensive overview that includes general characteristics, research focal points, the trajectory of evolution, and current emerging trends in this under-researched area.
UNASSIGNED: A systematic search was conducted using the Web of Science Core Collection (WOSCC) to identify articles related to A/R/M cervical cancer published between 2000 and 2022. Citespace and VOS viewer were the primary tools used to identify research focal points, intriguing future patterns, and to evaluate contributions and co-occurrences among authors, institutions, countries, and journals.
UNASSIGNED: A total of 1,001 original articles were identified, involving 6,387 authors from 66 countries and 1,474 institutions, and published across 366 academic journals. The United States contributed most significantly. The most productive researcher was Van der Burg SH from Leiden University Medical Center. The International Journal of Cancer and Cancer Research were identified as the most productive and influential journals, respectively. Analysis of co-citation clusters highlighted 25 clusters, primarily focusing on potential predictive biomarkers, dendritic cell-based tumor vaccines, therapeutic HPV vaccinations, peptide-based cancer vaccines, tumor immune microenvironments, and adoptive cell transfer (ACT). The latest significant trends in A/R/M cervical cancer immunotherapy research included ACT, CAR-T, and immune checkpoint inhibitors (ICIs), as revealed by keyword and reference burst detection.
UNASSIGNED: This pioneering study provides a detailed landscape of immunotherapy research in A/R/M cervical cancer. It underscores the importance of global collaboration, enriches our understanding of the immunology of A/R/M cervical cancer, expands on potential beneficiaries of immunotherapy, and explores clinical applications of various therapies, including therapeutic vaccines, adoptive cell transfer, and ICIs, particularly in combination with established treatments such as chemotherapy, radiotherapy, and targeted therapy.